Bartlett & Co Wealth Management’s Ginkgo Bioworks DNA Stock Holding History

Bartlett & Co Wealth Management’s Portfolio DNA Stock Details DNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$119	Hold	12	–	–	﹤0.01%	1314
2026 Q1	$119	Hold	12	–	–	﹤0.01%	1257
2025 Q4	$100	Hold	12	–	–	﹤0.01%	1215
2025 Q3	$175	Hold	12	–	–	﹤0.01%	1168
2025 Q2	$135	Hold	12	–	–	﹤0.01%	1217
2025 Q1	$68	Hold	12	–	–	﹤0.01%	1217
2024 Q4	$118	Hold	12	–	–	﹤0.01%	1109
2024 Q3	$98	Sell	12 -1	-8%	-$10	﹤0.01%	1112
2024 Q2	$167	Sell	13 -7	-35%	-$209	﹤0.01%	1115
2024 Q1	$928	Hold	20	–	–	﹤0.01%	1072
2023 Q4	$1.42K	Hold	20	–	–	﹤0.01%	1175
2023 Q3	$1.45K	Buy	20 +7	+54%	+$560	﹤0.01%	1096
2023 Q2	$930	Hold	13	–	–	﹤0.01%	1105
2023 Q1	$665	Buy	+13	New	+$824	﹤0.01%	1026

Other funds holding DNA

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

EAM

Erste Asset Management Vienna, Austria $12.9B AUM 52.69% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

ACG

Anchorage Capital Group New York $450M AUM 41.75% 1-Year Est. Return

Legal & General Group London, United Kingdom $480B AUM 42.84% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

JMFC

J.M. Forbes & Co Boston, Massachusetts $1.27B AUM 26.46% 1-Year Est. Return

Bartlett & Co Wealth Management's DNA Position: Q2 2026 in Review

Bartlett & Co Wealth Management held its Ginkgo Bioworks (DNA) position steady in Q2 2026 at 12 shares worth $119. The position accounts for ﹤0.01% of the portfolio, ranked #1314.

Bartlett & Co Wealth Management first reported a position in DNA in Q1 2023 and has held it in 14 quarters since. The position peaked at $1.45K in Q3 2023. 184 funds tracked by Wall St. Rank hold DNA as of Q2 2026.

Bartlett & Co Wealth Management held 12 shares of Ginkgo Bioworks worth $119 as of Q2 2026.
Bartlett & Co Wealth Management left its Ginkgo Bioworks share count unchanged in Q2 2026.
Ginkgo Bioworks made up ﹤0.01% of Bartlett & Co Wealth Management's portfolio in Q2 2026, its #1314 holding.
Bartlett & Co Wealth Management first reported a position in Ginkgo Bioworks in Q1 2023 and has held it in 14 quarters since.
Bartlett & Co Wealth Management's Ginkgo Bioworks position peaked at $1.45K in Q3 2023.
184 funds tracked by Wall St. Rank held Ginkgo Bioworks as of Q2 2026.

Based on Bartlett & Co Wealth Management's 13F filing for Q2 2026, filed 24 Jul 2026.